Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpaceSanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a "measured risk."Clinical DataImmunology & InflammationRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Clinical DataImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi immune drug hopeful posts mixed results in mid-stage testsNext: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
